Understanding the Natural History of Disease

Download our white paper “Understanding the Natural History of Disease” to discover the significant impact of natural history studies in drug development.  This understanding is important when developing treatments for rare diseases and conditions with limited existing knowledge.  Leveraging real-world data (RWD) and other sources of real-world evidence (RWE) are pivotal in natural history studies, offering comprehensive insights into disease progression.

Benefits of Natural History Studies:             

  • Prioritize indications for development
  • Design clinical development programs
  • Establish generalizability
  • Anticipate drug-drug interactions
  • Establish patient criteria for clinical studies
  • Identify patterns of drug use post-authorization

Natural history studies are essential in the drug development lifecycle, providing invaluable data that inform clinical trial design, regulatory strategy, and market access.

In this white paper UBC’s Annette Stemhagen, DRPH, FISPE, Eileen Moran, MBA, and Judy Lytle, PHD, MBEE, PMP explore why natural history studies should be considered a part of an overall evidence generation strategy.

Get started by completing the form to access our white paper: Understanding the Natural History of Disease.

Thank You for Connecting with UBC

Lorem ipsum dolor sit amet consectetur. Mi proin enim ipsum nascetur. Venenatis odio scelerisque non netus ac et pellentesque.

What You Can Expect Next

Lorem ipsum dolor sit amet consectetur. Cras aliquam erat eget magna sollicitudin.

Get Ready to Change Your Business

Lorem ipsum dolor sit amet consectetur. Mi proin enim ipsum nascetur. Venenatis odio scelerisque non netus ac et pellentesque.

Service Request

Bekki Bracken Brown

President & Chief Executive Officer

Bekki Bracken Brown serves as the President and CEO of UBC, guiding the company’s mission and values, including the improvement of access for patients to receive better outcomes. She oversees all aspects of UBC, such as operations, business growth strategy, sales and marketing, and acquisition support.

With over 20 years of industry experience, Ms. Brown brings knowledge from a successful career in senior management from her tenure at Quintiles, INC Research, and, most recently, with Syneos Health. She’s been a member of the North Carolina BIO Board of Directors since 2019. She is also a member of the Healthcare Businesswomen’s Association — Southeast Chapter and CHIEF, an organization that supports women executive leaders. Ms. Brown earned her bachelor’s degree at Duke University.